---
document_datetime: 2023-09-21 22:06:03
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_en.pdf
document_name: sugammadex-adroiq-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9047234
conversion_datetime: 2025-12-30 00:30:40.101089
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/23/1733/001 | Sugammadex Adroiq | 100 mg/ml  | Solution for injection | Intravenous use           | vial (glass)          | 2 ml                      | 10 vials    |
| EU/1/23/1733/002 | Sugammadex Adroiq | 100 mg/ml  | Solution for injection | Intravenous use           | vial (glass)          | 5 ml                      | 10 vials    |